{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:12:33Z","timestamp":1791508353181,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ijrobp.2015.04.038","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T16:54:16Z","timestamp":1430585656000},"page":"986-992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":180,"title":["A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma"],"prefix":"10.1016","volume":"92","author":[{"given":"Andra V.","family":"Krauze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten D.","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane J.","family":"Holdford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Tofilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-4877","authenticated-orcid":false,"given":"Kevin","family":"Camphausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.04.038_bib1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(11)70196-6","article-title":"Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial","volume":"12","author":"Senft","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"20","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00066-004-1220-7","article-title":"Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?","volume":"180","author":"Nieder","year":"2004","journal-title":"Strahlenther Onkol"},{"issue":"suppl 2","key":"10.1016\/j.ijrobp.2015.04.038_bib5","first-page":"S118","article-title":"Radiosurgery for high-grade glioma","volume":"3","author":"Binello","year":"2012","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-013-1139-x","article-title":"Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma","volume":"113","author":"Waters","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1021\/cr800504x","article-title":"Molecular targets for tumor radiosensitization","volume":"109","author":"Tofilon","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/0008-5472.CAN-03-2630","article-title":"Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275","volume":"64","author":"Camphausen","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by VPA","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib10","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-04-0537","article-title":"Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation","volume":"10","author":"Camphausen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib11","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor VPA","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib14","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"10","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib16","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1081\/CLT-120014645","article-title":"Valproic acid toxicity: Overview and management","volume":"40","author":"Sztajnkrycer","year":"2002","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0360-3016(91)90690-6","article-title":"Evaluation of bromodeoxyuridine in glioblastoma multiforme: A Northern California Cancer Center phase II study","volume":"21","author":"Phillips","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0360-3016(93)90229-O","article-title":"Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: A comparison of short versus long intravenous dose schedules (RTOG 86-12)","volume":"27","author":"Urtasun","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib20","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.2002.01.096","article-title":"Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study","volume":"20","author":"Kleinberg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0360-3016(83)90172-4","article-title":"A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study","volume":"9","author":"Nelson","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2000.18.6.1254","article-title":"Single-arm, open-label phase II study of intravenously administered tirapazamine and RT for glioblastoma multiforme","volume":"18","author":"Del Rowe","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib23","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1200\/JCO.1999.17.10.3143","article-title":"Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer trial 22933","volume":"17","author":"Miralbell","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib25","first-page":"240","article-title":"Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab\/everolimus as first-line treatment for patients with glioblastoma","volume":"10","author":"Hainsworth","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0360-3016(00)01458-9","article-title":"Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme","volume":"49","author":"Prados","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib28","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","article-title":"RTOG 0211: A phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients","volume":"85","author":"Chakravarti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib29","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"North Central Cancer Treatment Group study N0177. Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme. North Central Cancer Treatment Group study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2008.18.9639","article-title":"Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma","volume":"27","author":"Prados","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/neuonc\/noq071","article-title":"A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma","volume":"12","author":"Rosenfeld","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib33","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/neuonc\/nor130","article-title":"Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma","volume":"13","author":"Butowski","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib34","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with VPA use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2015.04.038_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615004423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615004423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T19:54:34Z","timestamp":1537646074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615004423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0360301615004423"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.038","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}